^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

Excerpt:
...Other JAK pathway alterations (eg, JAK2 fusions, EPOR fusions, SH2B3 deletions, IL7RA mutations) with or without CRLF2-R, or CRLF2-R with unknown JAK status as determined by a COG ALL Reference Laboratory...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

Excerpt:
...- SH2B adaptor protein 3 (SH2B3) deletions...
Trial ID:
Less C2 evidence
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia

Excerpt:
2 ALL xenografts with no identified JAK mutation or CRLF2 rearrangement (xenografts VII and VIII) had markedly decreased leukemia burden with ruxolitinib... an SH2B3 deletion and IL7R mutation were discovered in the sample corresponding to xenograft VIII....Taken together, these studies demonstrate the efficacy of ruxolitinib in ALL xenografts with a variety of JAK-activating lesions.
DOI:
https://dx.doi.org/10.1182%2Fblood-2012-03-415448